Abstract:Background: Although JAK (Janus Kinase) inhibitors have been widely applied to many types of aggressive tumors with continuously activated JAK/STAT signaling pathways, efficacious compounds against cervical cancer (CC) are still lacking, and chronic exposure to them inevitably results in drug resistance that often arises from compensatory activation of alternative signaling and survival pathways. Therefore, developing novel JAK inhibitors and identifying their partner compounds for combination therapy against CC, remains an unmet clinical need.Methods: In this study, by virtual screening the SPECS database, we selected out multiple JAK inhibitor candidates, validated their kinase activities and antitumor drug efficacies in various biochemical, cellular and in vivo xenograft models. Next, we screened a chemical library containing 2094 small molecules to identify compounds that act synergistically with the best JAK inhibitor obtained above in dampening CC cell propagation. Finally, the molecular mechanism of such synergistic effect was explored.Findings: Twenty potential small-molecule JAK inhibitors were identified by virtual screening, and the top 9 ranking compounds were validated by biochemical assays. AH057, the best JAK inhibitor identified, can effectively block JAK/STAT pathways by directly inhibiting JAK1/2 activities, and exhibits potent antitumor effects including compromised cell proliferation and invasion, increased apoptosis, arrested cell cycles and impaired tumor progression in a xenograft model. Among all cell lines examined, CC cell lines were the most sensitive to AH057. Further, based on the calculated Bliss synergy scores, SGI-1027, a DNMT1 inhibitor, was identified as the best compound that works in high synergy with AH057. The combination of AH057 and SGI-1027 potently induced cell cycle arrest at G1 phase partially through Cyclin D1 and Cyclin A2, and apoptotic cell death that is linked to PARP, Caspase-3, Bcl-xL and Survivin.Interpretation: A novel oral small-molecule JAK1/2 inhibitor AH057 with definitive antitumor efficacy against CC is identified in this study. The combination of AH057 with the DNMT1 inhibitor SGI-1027 synergistically impairs cancer cell propagation via induced apoptosis and cell cycle arrest, likely by acting on a same group of downstream effector molecules that are dually controlled by JAK1/2 and DNMT1. This study provides preclinical support for launching a clinical trial to evaluate the safety and efficacy of this drug combination in patients with CC and other malignant tumors.Funding Statement: This work was supported by grants from the National Key Research and Development Program of China (2016YFA0101201, 2016YFA0100303, 2017YFD0200505), and the National Natural Science Foundation of China (31601103, 31872022).Declaration of Interests: YJW, BK and JZ have a pending patent application titled “Identification of a novel JAK1/2 inhibitor and its synergistic drug combinations against human cancers”. The other authors declared no conflicts of interest.Ethical Approval Statement: The Experimental Animal Ethics Committee of Zhejiang University has approved the animal protocol.

Preclinical Evaluation of JAB-2485, a Potent AURKA Inhibitor with High Selectivity and Favorable Pharmacokinetic Properties

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

2-Phenoxy-3, 4′-bipyridine derivatives inhibit AURKB-dependent mitotic processes by disrupting its localization

Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy

Development and Biological Evaluation of a Novel Aurora A Kinase Inhibitor

An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor

AURKA inhibition shows promise as a therapeutic strategy for ARID1A-mutant colorectal cancer

Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors

In Vitro and in Vivo Characterization of a Benzofuran Derivative, a Potential Anticancer Agent, As a Novel Aurora B Kinase Inhibitor.

Identification of a Novel Oral Small-Molecule JAK1/2 Inhibitor and Its Potent Synergistic Drug Combinations Against Cervical Cancer

The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.

Selective Aurora A-TPX2 Interaction Inhibitors Have In Vivo Efficacy as Targeted Antimitotic Agents

Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins

M1611 Epigenetic Characterization of a Novel Tumor Suppressor Gene, RNF180, in Gastric Cancer and Its Application in Noninvasive Cancer Detection

Abstract 5806: Discovery of a long half-life AURKA inhibitor to treat MYC-amplified solid tumors as a monotherapy and in combination with everolimus

Breaking the 'undruggable' barrier: Revealing molecular mechanisms in Aurora Kinase A/Myc protein interplay targeting cancers

Therapeutic Rationale to Target Highly Expressed Aurora Kinase A Conferring Poor Prognosis in Cholangiocarcinoma

Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression

Discovery of N -benzylbenzamide-based allosteric inhibitors of Aurora kinase A

Selective Aurora A-TPX2 interaction inhibitors have efficacy as targeted anti-mitotic agents

Design, Synthesis, and Biological Evaluation of 2‐Aminothiazole Derivatives as Novel Checkpoint Kinase 1 (CHK1) Inhibitors